Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Erika Bågeman"'
Autor:
Gustav Ullenhag, Anne Månsson Kvarnhammar, Charlotte Russell, Jeffrey Yachnin, Ana Carneiro, Dorte Nielsen, Kristoffer Staal Rohrberg, Lena Schultz, Erika Bågeman, Camilla Wennersten
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/3e96f87529834f328a68a94048cd2514
Autor:
Jeffrey Yachnin, Gustav Ullenhag, Ana Carneiro, Dorte Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Lena Schultz, Erika Bågeman, Camilla Wennersten, Charlotte Russell
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody developed as a first in class tumor-localizing CTLA-4 antibody for improved efficacy and reduced toxicity. Methods The study (NCT03782467) is a first-in-human dose escal
Autor:
Anne Moore, Erika Bågeman, Susan A. Melin, P Klein, M. Melisko, Tessa Cigler, ES Ver Hoeve, Glen D. Park, Sara A. Hurvitz, HS Rugo
Publikováno v:
Cancer Research. 77:P5-11
Background: Most women consider hair to be an important part of body image. Alopecia is an emotionally traumatic side effect for breast cancer patients undergoing adjuvant chemotherapy. The DigniCap™ Scalp Cooling System is the first scalp cooling
Autor:
Gustav J. Ullenhag, Kristoffer Staal Rohrberg, Erika Bågeman, Charlotte A. Russell, Jeffrey Yachnin, Ana Carneiro, Dorte Nielsen, Anne Månsson Kvarnhammar, Camilla Wennersten
Publikováno v:
Cancer Research. 80:CT145-CT145
ATOR-1015 is evaluated in this first-in-human phase 1 study for safety and tolerability, as well as pharmacokinetics, immunogenicity and clinical efficacy (NCT03782467). ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody developed
Autor:
Anne Månsson Kvarnhammar, Jeffrey Yachnin, Lena Schultz, Charlotte A. Russell, Gustav J. Ullenhag, Kristoffer Staal Rohrberg, Erika Bågeman, Camilla Wennersten, Dorte Nielsen, Ana Carneiro
Publikováno v:
Journal of Clinical Oncology. 38:3061-3061
3061 Background: ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody developed to be a next generation CTLA-4 antibody with enhanced immune activation and tumor-directed activity for improved efficacy and reduced toxicity. Methods:
Autor:
Anne Månsson Kvarnhammar, Erika Bågeman, Jeffrey Yachnin, Dorte Nielsen, Ana Carneiro, Anna Dahlman, Charlotte A. Russell, Gustav J. Ullenhag, Camilla Wennersten, Kristoffer Staal Rohrberg
Publikováno v:
Journal of Clinical Oncology. 37:TPS2653-TPS2653
TPS2653 Background: ATOR-1015 is a human bispecific IgG1 antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and the tumor necrosis factor receptor superfamily member 4, OX40 (also known as CD134). Both in vitro and in vivo, ATOR-
Publikováno v:
British Journal of Cancer
BACKGROUND: CYP2C8/9 polymorphisms may influence breast cancer-free survival after diagnosis due to their role in the metabolism of tamoxifen, paclitaxel, and other chemotherapy. cytochrome P450 (CYP)2C8/9 metabolise arachidonic acid to epoxyeicosatr
Publikováno v:
Molecular Genetics and Metabolism. 89:381-389
Most, but not all, studies have found that women with a high urinary 2-hydroxyestrogen (2OHE) to 16 alpha-hydroxyestrone (16 alpha OHE1) ratio are at reduced risk for breast cancer and have a better prognosis. The aim was to identify factors associat
Publikováno v:
British Journal of Cancer
BRCA1/2 mutations predispose to early-onset breast cancer, especially after oral contraceptive (OC) use and pregnancy. However, the majority of breast cancers might be due to more prevalent low-penetrance genes, which may also modify the risk in BRCA
Autor:
Sara A. Hurvitz, Jules T. Mitchel, Elizabeth S. Ver Hoeve, Glen D. Park, P Klein, Anne Moore, Erika Bågeman, Laura J. Esserman, Hope S. Rugo, Susan A. Melin, Michelle E. Melisko, Tessa Cigler, Ralph B. D'Agostino
Publikováno v:
JAMA, vol 317, iss 6
ImportanceChemotherapy-induced alopecia is a common and distressing adverse effect. In previous studies of scalp cooling to prevent chemotherapy-induced alopecia, conclusions have been limited.ObjectivesTo evaluate whether use of a scalp cooling syst